Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists

Abstract

The use of a compound of formula (I): wherein Ris selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NRR, NRCONR, NRCONRR,NRCORand NRSOR; Ris selected from aryl attached via an unsaturated carbon; Ris selected from H, alkyl, COR, COR, CONRR, CONRNRRand SOR; R, Rand Rare independently selected from H, alkyl and aryl or where Rand Rare in an NRRgroup, Rand Rmay be linked to form a heterocyclic group, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and Ris selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se